A groundbreaking clinical trial has revealed that a new cancer treatment, amivantamab, can completely eliminate tumours in patients with advanced head and neck cancers. This innovative jab, which is administered subcutaneously rather than through traditional intravenous methods, is offering new hope to individuals whose cancers have proven resistant to conventional therapies.
Unprecedented Results in Cancer Treatment
The international OrigAMI-4 trial, conducted across 11 countries, has showcased extraordinary outcomes for patients with tumours that have either metastasised or recurred after previous treatments. Researchers reported that over one-third of the 102 participants experienced significant tumour reduction, with 15 patients achieving complete remission. These results were presented at the American Society of Clinical Oncology (ASCO) annual meeting, underscoring the potential of this treatment in the oncology landscape.
Kevin Harrington, a leading figure in biological cancer therapies at the Institute of Cancer Research in London and a consultant oncologist at the Royal Marsden NHS Foundation Trust, commented on the significance of the findings: “These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This treatment has the potential to benefit many thousands of patients each year.”
The Mechanism Behind Amivantamab
Amivantamab, developed by Johnson & Johnson, operates through a multi-faceted approach. It inhibits both the epidermal growth factor receptor (EGFR) and the MET pathway, which cancer cells frequently exploit to evade treatment. Additionally, it stimulates the immune system to target and destroy cancer cells. This innovative mechanism is particularly relevant for patients with head and neck cancers, which rank as the sixth most common cancer globally.
The trial’s participants, all suffering from head and neck cancers that did not include HPV-positive oropharyngeal squamous cell carcinoma, were primarily those with limited treatment options. The results from this demographic are vital, given the challenges associated with treating non-HPV cancers, which are notoriously more resistant to therapies.
Patient Experiences and Quality of Life
Among the patients benefiting from this trial is 56-year-old Carl Walsh, who was diagnosed with tongue cancer in May 2024. After unsuccessful treatments involving chemotherapy and immunotherapy, Walsh enrolled in the OrigAMI-4 trial in July 2025. He expressed his gratitude for the treatment, stating, “I now feel able to live a normal life. Before starting the trial, I struggled to speak properly and found eating difficult because of the swelling and pain. Since beginning treatment, the swelling has reduced significantly, and my pain levels have improved considerably.”
Walsh’s experience highlights the treatment’s convenience; unlike traditional cancer therapies, amivantamab is delivered via a small injection every three weeks, resulting in a more manageable outpatient experience. The side effects reported were primarily mild to moderate, with less than 10% of participants discontinuing treatment due to adverse reactions.
Survival Rates and Future Implications
The trial results indicate that patients receiving amivantamab had a median survival rate of 12.5 months, a notable improvement given the poor prognosis typically associated with advanced head and neck cancers. Prof. Kristian Helin, chief executive of the Institute of Cancer Research, emphasised the importance of these findings: “This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options.”
As amivantamab continues to undergo evaluation in approximately 60 additional clinical trials targeting various cancers, including lung, colorectal, brain, and gastric cancers, the potential for broader applications is promising.
Why it Matters
The emergence of amivantamab represents a significant advancement in the fight against cancer, particularly for patients facing limited options due to treatment resistance. With its innovative delivery method and impressive efficacy, this treatment could redefine standards of care for individuals battling advanced malignancies. As researchers continue to explore its full potential, the hope is that such breakthroughs will pave the way for more effective therapies, ultimately improving survival rates and quality of life for countless patients worldwide.
